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Abstract
Background: Every year in Europe about 25,000 infants are born extremely preterm. These infants have a 20%
mortality rate, and 25% of survivors have severe long-term cerebral impairment. Preventative measures are key to
reduce mortality and morbidity in an extremely preterm population. The primary objective of the SafeBoosC phase
II trial is to examine if it is possible to stabilize the cerebral oxygenation of extremely preterm infants during the first
72 hours of life through the application of cerebral near-infrared spectroscopy (NIRS) oximetry and implementation
of an clinical treatment guideline based on intervention thresholds of cerebral regional tissue saturation rStO2.
Methods/Design: SafeBoosC is a randomized, blinded, multinational, phase II clinical trial. The inclusion criteria are:
neonates born more than 12 weeks preterm; decision to conduct full life support; parental informed consent; and
possibility to place the cerebral NIRS oximeter within 3 hours after birth. The infants will be randomized into one of
two groups. Both groups will have a cerebral oximeter monitoring device placed within three hours of birth. In the
experimental group, the cerebral oxygenation reading will supplement the standard treatment using a predefined
treatment guideline. In the control group, the cerebral oxygenation reading will not be visible and the infant will be
treated according to the local standards. The primary outcome is the multiplication of the duration and magnitude
of rStO2 values outside the target ranges of 55% to 85%, that is, the ‘burden of hypoxia and hyperoxia’ expressed
in ‘%hours’. To detect a 50% difference between the experimental and control group in %hours, 166 infants in total
must be randomized. Secondary outcomes are mortality at term date, cerebral ultrasound score, and interburst
intervals on an amplitude-integrated electroencephalogram at 64 hours of life and explorative outcomes include
neurodevelopmental outcome at 2 years corrected age, magnetic resonance imaging at term, blood biomarkers at
6 and 64 hours after birth, and adverse events.
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Discussion: Cerebral oximetry guided interventions have the potential to improve neurodevelopmental outcome
in extremely preterm infants. It is a logical first step to test if it is possible to reduce the burden of hypoxia and
hyperoxia.
Trial registration: ClinicalTrial.gov, NCT01590316
Keywords: Randomized clinical trial, Preterm, Near infrared spectroscopy, Protocol
Background
Every year in Europe about 25,000 infants are born ex-
tremely preterm. They are at high risk of death and those
surviving may develop cerebral impairment; mortality is
about 20% [1], and about 25% of survivors live with either
cerebral palsy or low intelligence quotient [2,3].
All organs are immature when an infant is born more
than 12 weeks before term. The immaturity and functional
limitations of the brain, lungs, heart, intestine, kidneys,
liver, and endocrine system contribute to acute condition
of the extremely preterm infant. For instance, the immatur-
ity of the brain can result in death or neuropsychological
deficits such as cerebral palsy and cognitive deficits [4].
The most easily identifiable type of brain damage in ex-
tremely preterm infants is periventricular-intraventricular
brain hemorrhage (PV-IVH) [5]. The severity varies; how-
ever, in its most severe form it predicts high probability of
cerebral palsy, hydrocephalus, or death [6,7]. Periventricu-
lar leucomalacia (PVL) is non-hemorrhagic white matter
damage and a strong predictor of cerebral palsy [8].
The mechanisms of brain damage in preterm infants
are complex. Some of the mechanisms are evoked before
birth or even before the start of delivery such as a fetal
inflammatory response induced by infection ascending
to the fetal membranes [1]. Also, late effects such as in-
sufficient nutrition and poor growth during the first
months of life may play a role [9]. The first days after
birth are likely to be of particular importance, and the
circulatory adaption to birth is problematic. Moreover,
birth is a change from a state of low oxygen pressure
(‘Mount Everest in utero’) to a state of ‘normoxemia’.
The following postnatal factors have been shown or are
thought to be associated with brain injury: respiratory
distress syndrome [10], hypocapnia due to inadvertent
hyperventilation [11], low blood pressure [12], pertur-
bations in arterial and venous pressure [13], and low
cerebral blood flow [14]. In addition, clinical and experi-
mental evidence suggest that hyperoxygenation is dan-
gerous due to lack of a developed antioxidant defense
system [15].
Preventative measures are key to reduce mortality and
morbidity in an extremely preterm population. Near-
infrared spectroscopy (NIRS) has been used to monitor
tissue oxygenation since the mid-1980s. The quantifica-
tion of the tissue oxygen saturation of hemoglobin (rStO2)
in percentage from 0 to 100% has been possible for 10
years. Data from almost 400 preterm infants using NIRS
oximeter INVOS 4100/5100 with the adult SomaSensor
(SAFB-SM) showed that the normal ranges of rStO2 to be
from 55% to 85% (unpublished data from the group of
Lemmers and van Bel, Utrecht). Important clinical infor-
mation can be gained from cerebral NIRS oximetry in ne-
onates. rStO2 has been shown to be a predictor of
outcome in hypoxic-ischemic encephalopathy [15] and to
be low in infants with a patent ductus arteriosus [16].
However, no solid evidence of the clinical utility of NIRS
in preterm infants exists. There is a lack of randomized
clinical trials. Thus, further research on the benefits and
harms of cerebral monitoring using NIRS as a part of clin-
ical management of premature infants is needed.
Objectives
The primary objective of the SafeBoosC phase II trial is
to examine if it is possible to stabilize the cerebral oxy-
genation of extremely preterm infants during the first 72
hours of life through the application of cerebral NIRS
oximetry and implementation of an rStO2-specific clin-
ical treatment guideline. We hypothesize that using the
treatment guideline to respond to cerebral monitoring
readings outside the target range will reduce the burden
of hypoxia and hyperoxia and consequently reduce brain
injury of extremely preterm newborns.
Methods/Design
The study will be conducted according to Good Clinical
Practice guidelines and the Declaration of Helsinki. The
protocol will be approved by the Ethics Committees of
each participating center involved and if necessary by
national law by the relevant competent authority. Writ-
ten informed consent must be obtained before inclusion
of an infant.
Ethical approvals
By 01-March-2013 the study had been approved by
Clinical Research Ethics Committee of the Cork Teach-
ing Hospitals (EMC 3 (xxx) 03/07/12); NRES Commit-
tee East of England - Cambridge South (12/EE/0329);
Ethikkommission Medizinische Universität Graz (24-
261 ex (11/12)); Commissie Medische Ethiek Van De
Universitaire Ziekenhuizen Kuleuven (ML8536); De
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Videnskabetiske Komiteer - Region Hovedstaden (H-4-
2012-028); CPP Sud-Est III - Lyon (HCL/P 2012.728);
Direzione Scientifica - Comitato di Etica - The IRCCS
Fondazione Ca’ Granda Ospedale Maggiore Policlinico
(549/12 - all.3); Medisch Ethische Toetsingscommissie -
Universitair Medisch Centrum Utrecht) (WAG/rc/12/
036774), and Comité Ético de Investigación Clínica del
Hospital Universitario ‘La Paz’ de Madrid (15/2011).
Burden of hypoxia and hyperoxia
The burden of hypoxia is the multiplication of duration
and magnitude of rStO2 values below 55%. The burden
of hyperoxia is the multiplication of duration and mag-
nitude of rStO2 values above 85%. The sum of the bur-
den of hypoxia and hyperoxia is expressed in ‘%hours’.
Trial design
The SafeBoosC is an investigator-initiated randomized,
blinded, multinational, phase II feasibility clinical trial
designed to include extremely preterm infants from 12
European countries.
Population
The trial population is extremely premature infants.
Inclusion criteria
The inclusion criteria are: neonates born more than 12
weeks preterm (gestational age up to 27 weeks and 6 days),
decision to conduct full life support, parental informed
consent, and possibility to place the cerebral NIRS oxi-
meter within 3 hours after birth.
Exclusion criteria
Exclusion criteria are a decision not to provide life sup-
port or lack of informed consent.
Randomization
Web-based randomization is conducted centrally at the
Copenhagen Trial Unit according to a computer-generated
allocation sequence with a varying block size concealed for
the investigators. The allocation is stratified for gestational
age (<26 weeks or ≥26 weeks). Singleton infants will be
randomized individually. Twins will be randomized as a
‘pair’; that is, both siblings will be allocated to the same
treatment group. If not all infants from a multiple birth
can be included due to lack of equipment, it is allowable to
include as many as possible always starting with the infant
born last and then the infant born second last and so forth.
Intervention
The preterm infants will be randomized into one of two
groups; both groups will have a cerebral oximeter moni-
toring device placed within three hours of birth. In the
experimental group, the cerebral oxygenation reading
will be visible and the infant will be treated accordingly
using a predefined treatment guideline For the control
group, the cerebral oxygenation reading will NOT be vi-
sible and the infant will be treated according to local
guidelines.
Devices for cerebral NIRS monitoring
Cerebral oximetry by NIRS in extremely preterm infants
has no reference standard, however, this clinical inves-
tigation will use the INVOS 5100c™ with the adult
SomaSensor™ as reference for NIRS device eligibility. The
application of the adult sensor in this population is consid-
ered safe as no serious adverse effects relating to the oxim-
eter, such as skin burns etcetera, were encountered in these
infants. Device eligibility is tested by comparison of abso-
lute values, reproducibility and sensitivity to changes in
oxygenation on the adult arm [17]. Absolute values and dy-
namic range within 5 percentage points of the INVOS and
reproducibility better than 6% are the predefined thresh-
olds. So far eligible devices for the present trial include
INVOS 5100C™ with Adult SomaSensor™, NIRO 200NX™
with small probe-holder, and NONIN EQUANOX 7600™
with adult sensor Model 8004CA™ [17]. The use of adult
sensors in the neonates will need approval in some coun-
tries from a competent authority.
The devices will be locked in a box and all data will be
sent to a laptop real time. Software has been developed
that shows the current rStO2 with trend lines and saves
the data as comma separated values. Accordingly, rStO2
data in both the experimental and the control group will
be collected; however, rStO2 in the control group will
not be visible to the health-care professionals. Moreover,
all trial-related interventions and sensor re-positioning,
as well as physiological parameters such as blood pres-
sure, mean airway pressure, etcetera, will be registered
by the health-care professionals.
Treatment guideline
The treatment guideline aims at controlling the oxygen
delivery to the brain. In brief, it suggests a non-prioritized
number of possible interventions if the rStO2 is out of
range. For ventilatory support, the interventions could be
to change the inspiratory oxygen fraction, the mean airway
pressure, or the minute ventilation. For hemodynamic
support, the possible interventions include inotropics/va-
sopressors to increase blood pressure, medical closure of
the ductus arteriosus, or red blood cell transfusion to in-
crease oxygen capacity and intravascular volume. The ra-
tionale for and content of the treatment guideline are
described in detail in a complementary paper (in press).
Trial duration
Monitoring by cerebral NIRS oximetry will start as soon
as possible or within 3 hours after birth. The interven-
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tion will last for 72 hours. The infants will be followed
up for 24 months after term date.
Demographics
Known pregnancy-related risk factors will be registered,
for example, preeclampsia, chorioamnionitis, maternal
smoking, corticosteroid administration before birth, and
multiple births. Moreover, known risk factors during the
first days of life, such as gestational age, birth weight,
Apgar scores, umbilical cord pH, respiratory distress,
mode of ventilatory support, and presence of a patent
ductus arteriosus, will also be registered.
Outcome measures
The primary outcome is the burden of hypoxia and
hyperoxia in % hours during the first 72 hours after
birth. The secondary outcomes are all-cause mortality at
term date, cerebral ultrasound score [18], and interburst
intervals on an amplitude-integrated electroencephalo-
gram (aEEG) at 64 hours of life. Exploratory outcomes
include blood biomarkers brain fatty acid binding pro-
tein (BFABP), neuroketal, and S100β [19-21] at 6 and 64
hours; and serious and non-serious adverse reactions
(SARs); burden of hypoxia; burden of hyperoxia; neo-
natal morbidities including bronchopulmonary dys-
plasia (BPD), necrotizing enterocolitis (NEC), and
retinopathy of prematurity (ROP); brain injury on mag-
netic resonance imaging (MRI), that is, brain injury
score according to Woodward score plus cerebellum
scoring [22], volumetric measurements, cortical folding
with formation of the sulci, and diffusion tensor im-
aging; and psychomotor impairment according to neu-
rodevelopmental scales at 24 months after term date
(Table 1). Analysis of outcome measures will be blinded
to group allocation. When possible the analysis will be
centralized.
Statistical considerations
Sample size
In a sample of 23 infants born before 28 weeks of gesta-
tion the mean burden of hypoxia and hyperoxia was
76.0%hours ± standard deviation (SD) of 83.2%hours.
With a 50% reduction of the area outside the normal
range of oxygenation in %hours in the experimental
group compared with the control group as the minimal
clinically significant difference, a SD of the area outside
the normal range of 83.2%hours, a type I error (alpha) of
5%, and a type II error of 0.05 (power of 95%) the inclu-
sion of 75 extremely preterm infants in the experimental
group and 75 extremely preterm infants in the control
group is required. However the prevalence of twins
among extremely preterm infants is about 30%. The
within-cluster correlation diminishes the statistical
power. To account for this the sample size needs to be
multiplied by the ‘design effect’ [23]:
Design effect ¼ 1þ n’–1ð Þ % ICC
ICC = intraclass correlation coefficient
n’ = average cluster size
The twin ICC is unknown for cerebral oximetry. A
pragmatic solution is to increase the sample size to 166
in the present study with a continuous outcome and
only about 30% of infants in clusters of two. This corres-
ponds to an ICC of 0.33.
Data analysis
All analyses will be intention to treat analyses conducted
blinded with two-sided tests at the 0.05 level of signifi-
cance. A fully specified statistical analysis plan for the
main analysis, including programming details, will be
written and approved before unmasking.
The statistical analysis is sophisticated by the fact that
up to 30% of the births may be twin births where both
siblings will be randomized to the same arm creating
multiple clusters of two observations that may be corre-
lated. Shaffer et al. [24] found that for this type of data
without covariates added a mixed effects model with
random intercept is the preferred model for continuous
outcome data while ordinary logistic regression is pre-
ferred for binary data. Sauzet et al. [25] studied the ef-
fect of including adjusting covariates in the model for a
continuous outcome variable. They found not negligible
and similar bias for estimated coefficients whether a
mixed model or a linear regression model was used.
Standard errors were underestimated using linear
models thus inflating the type I error.
A mixed model with random intercept for continuous
outcome variables and ordinary logistic regression for
binary (and ordinal) outcome variables will be used. The
analyses will be adjusted for the protocol specified vari-
ables (gestational age category and trial site indicator)
and (following multiple imputations if necessary) will be
the primary results. Since the intracluster correlation
may cause parameter estimate bias in the presence of
covariates (other that the intervention indicator) for
continuous outcome variables an unadjusted analysis
will also be done. If the results of the adjusted and un-
adjusted analysis differ markedly the results will be
discussed. The effect of covariates is unknown for binary
outcome variables.
If for a specified statistical model to be used in one of
the above analyses of primary and secondary outcome
measures Little’s test is significant (P <0.05) and the per-
cent missing cases >5%, multiple imputations will be ap-
plied to adjust for values missing at random.
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To assess the spectrum of potential bias resulting from
data missing not at random the following sensitivity ana-
lysis will be done for the primary outcome measure: let A
be the group with a beneficial effect (low outcome value) as
compared to the other group (group B), min be the mini-
mum value, and max the maximum value in the material.
Two estimates of the coefficient (c) of the intervention indi-
cator will then be calculated where missing values in A are
replaced by the maximum value found in the material and
missing values in B are replaced by minimum value found
in the material and vice versa. Since the imputation may
impact the standard error of the parameter estimate in an
unpredictable way the standard error of the primary ana-
lysis will be used in each case to test if the estimate deviates
significantly from 0.
The null hypothesis corresponding to the primary out-
comemeasure is tested at the 0.05 level of significance. If the
test is significant the three secondary outcomes (interburst
Table 1 Outcome measures of the SafeBoosC phase II trial
Tools Outcomes Time points
Primary outcome
Cerebral NIRS oximeter • Burden of hypoxia and hyperoxia • During the intervention until 72 hours after birth
Secondary outcomes
aEEG/EEG • Interburst interval (IBI) • 64 hours after birth
cUS • Worst Brain injury score (1 to 3) of five cUSs • At 1 to 4 days after birth
• At 7 days after birth
• At 14 days after birth
• At 35 days after birth
• At term date
Medical records • All-cause mortality Term date
Exploratory outcomes
Medical records • Serious adverse reactions • During the first 7 days of life
• Non-serious adverse reactions
Cerebral NIRS oximeter • Burden of hypoxia • During the intervention until 72 hours after birth
• Burden of hyperoxia
Blood samples • BFABP • 6 hours after birth
• Neuroketal • 64 hours birth
• S100β
Medical records • Neonatal morbidities: • Term date
• NEC stage 2 to 3
• ROP stage 3+ and above
Medical records Neonatal morbidities: • At 36 weeks
• BPD
aEEG/EEG • Power in delta band • 64 hours after birth
• Power in theta band
• Power in alpha band
• Power in beta band
MRI • Brain injury score (Woodward) • At term date
• Volumetric
• Cortical folding diffusion tensor imaging
BSID-III • Cognitive score • 24 months after term date
• Verbal score
• Motor score
ASQ-III • Total score • 24 months after term date
aEEG, amplitude-integrated electroencephalogram; ASQ-III, Ages and Stages Questionnaires, Third Edition™; BFABP, brain fatty acid binding protein; BPD,
bronchopulmonary dysplasia; BSID-III, Bayley Scales of Infant and Toddler Development, Third Edition™; cUS, cerebral ultrasound; EEG, electroencephalogram; MRI,
magnetic resonance imaging; NEC, necrotizing enterocolitis; NIRS, near-infrared spectroscopy; ROP, retinopathy of prematurity.
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interval (IBI) at 64 hours, cerebral ultrasound (cUS), all cause
mortality at term) will be tested using alpha = 0.05 and
Hommel’s procedure as adjustment for multiplicity [26]. The
statistical analysis will be done using SPSS™ version 17 or
later (IBMCorporation, NewYork, USA).
Safety
Serious adverse reactions and suspected unexpected serious
adverse reactions (SUSARs) will be recorded and reported
according to the ISO14155:2011 ‘Clinical Investigation of
Medical Devices’ [27] to the appropriate competent author-
ities and ethics committees. Since the extremely preterm
population is a high-risk population it has been decided
that only events with a certain/likely/probable relation to
the intervention will be reported whereas all other non-
serious and serious adverse events will not be reported.
Ethical considerations
The research question whether monitoring of cerebral oxy-
gen saturation levels in the first 72 hours after birth and
subsequent treatment according to predefined guidelines
can prevent brain injury and maybe death in extremely pre-
term infants can only be answered in that very population.
There is a potential benefit to the infants in the experimen-
tal group. Currently, there are no randomized clinical trials,
thus no conclusive evidence, on the benefit of NIRS moni-
toring in preterm infants, and there is no evidence of risk
of harm from cerebral oximetry in this population. There-
fore, a small risk of harm from the sensor or manipulation
among both the experimental and the control group cannot
be excluded. It is thus considered ethically acceptable that
the control group receives ‘treatment as usual’. All inter-
ventions proposed in the treatment guideline are com-
monly used in this patient group.
Due to the clinical nature of the trial population, the
extremely preterm infants, stress reactions related to the
manipulation during positioning and repositioning of the
cerebral NIRS oximeter sensors can occur. It is, however,
not considered to give substantially more risk or discomfort
compared with no intervention.
To minimize parental concern, it has been decided that
multiple births will be randomized together and undergo
allocation to the same intervention.
To obtain evidence-based knowledge on the benefit
and harms of cerebral monitoring using NIRS as part of
clinical management of premature infants, a large-scale
randomized clinical trial with a clinically relevant out-
come, such as survival without neurodevelopmental def-
icit is needed. The SafeBoosC phase II trial presented
here serves as a feasibility trial for such a phase III trial.
Discussion
SafeBoosC phase II trial tests the hypothesis that cere-
bral oxygenation in extremely preterm infants can be
stabilized to the extent that the burden of hypoxia and
hyperoxygenation can be reduced by 50%. Furthermore,
the trial includes numerous secondary and exploratory
outcomes that explore its feasibility and usefulness in a
multinational trial and hence help with the planning of a
phase III trial with a clinically relevant and patient-
relevant primary outcome.
The trial design of the SafeBoosC phase II has poten-
tial problems. Both the interventional and the control
group will be monitored with NIRS and will be exposed
to the same risks regarding the positioning of the sensor
such a burns and increased manipulation of the infant,
thus a higher drop out in the control group is possible.
Hopefully a low frequency of adverse events and reac-
tions and full support from clinical staff will minimize
this problem. Moreover, the poor reproducibility when
changing sensor position [17,28] could introduce a bias
as the nurses caring for infants in the intervention group
will see the rStO2 and when the value is out of range
may reposition the sensor to try to obtain a within-range
value. A standard operating procedure for repositioning
will be available and all repositioning will be registered
and analyzed to estimate the magnitude of this problem.
Cerebral oximetry has rather poor precision with the
present technology. The devices that are commercially
available do not give identical values. Furthermore, only
a statistically based target range is available, rather than
a target range defined by minimal risk of brain injury.
All this, however, does not subtract from the relevance
of the present trial. The trial will test the possibility of
managing cerebral oxygenation, regardless of its precise
value or its precise clinical relevance. In contrast to this,
a phase III trial is critically dependent on the precision
of cerebral oximetry as well as on an appropriate target
range.
Brain hypoxia and hyperoxia are one of the several
likely causes of neurodevelopmental deficit in extremely
preterm infants. Therefore, it is not likely that the risk of
deficits can be reduced by more than 5 percentage
points - from 25 to 20%. An effect on mortality is not
foreseen. Therefore, a phase III trial with survival with-
out neurodevelopment deficit as the primary outcome
will have to include about 4000 infants.
In conclusion, cerebral oximetry has the potential to im-
prove neurodevelopmental outcome in extremely preterm
infants. It is a logical first step to test if it is possible to re-
duce the burden of hypoxia and hyperoxia significantly by
the combination of cerebral oximetry with a predefined
clinical guideline.
Trial status
Patient recruitment is ongoing (01-nov-2012) and can be
accessed at http://www.safeboosc.eu.
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